Kiromic BioPharma announced that the FDA has authorized the company’s investigational new drug, or IND, application to initiate a Phase 1 clinical trial to evaluate Deltacel for patients with non-small cell lung cancer, or NSCLC.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRBP: